SCHEMBL3979939

SCHEMBL3979939

CCS(=O)(=O)Nc1ccc2ccccc2c1C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 3/20 0.68
METAP1 P53582 1/20 0.68
HPGD P15428 3/20 0.47
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 3/20 0.47
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HSD17B10 Q99714 2/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 1/20 0.47
GFER P55789 1/20 0.47
CYP1A2 P05177 1/20 0.45
GLA P06280 1/20 0.45
CYP2C19 P33261 1/20 0.45
PSIP1 O75475 1/20 0.44
LMNA P02545 1/20 0.43
G6PD P11413 1/20 0.41
KCNA5 P22460 1/20 0.41
KEAP1 Q14145 1/20 0.41
MCL1 Q07820 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3981564 0.90 METAP2 (0.63) METAP2METAP1HPGDKMT2AKDM4E
SCHEMBL3979514 0.88 METAP2 (0.60) METAP2METAP1PARP14
SCHEMBL3983370 0.86 METAP2 (0.64) METAP2METAP1HPGDKMT2AKDM4E
SCHEMBL3982567 0.85 METAP2 (0.71) METAP2METAP1HPGDKMT2AKDM4E
SCHEMBL3985088 0.82 METAP2 (0.60) METAP2METAP1HPGDKMT2AKDM4E
SCHEMBL3986500 0.81 METAP2 (1.00) METAP2METAP1KMT2AMEN1ALDH1A1
SCHEMBL3985999 0.78 METAP2 (0.74) METAP2METAP1KMT2AMEN1ALDH1A1
SCHEMBL3984291 0.78 METAP2 (0.82) METAP2METAP1ALDH1A1MAPTCYP1A2
SCHEMBL4277652 0.78 METAP2 (0.69) METAP2METAP1HPGDKMT2AMEN1
SCHEMBL28056928 0.78 METAP2 (0.60) METAP2METAP1HPGDKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-04-08 US claimed
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 US disclosed
EP-1549613-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY Abbott Laboratories (US) 2005-07-06 EP disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 US disclosed
WO-2004033419-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY ABBOTT LABORATORIES (US) 2004-04-22 WO disclosed
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885METAP1 2/4885HPGD 3416/4885
US-20040068012-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885METAP1 2/4885HPGD 3416/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885METAP1 2/4885HPGD 3416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.